Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.41 | N/A | -0.97% |
management commentary, guidance changes, and full analysis available with Pro.
| -0.97% |
Tone: Cautiously Optimistic
Overall, management remains focused on long-term growth despite the slight EPS miss. They emphasized the strength of their product portfolio.
Management expressed confidence in ongoing product pipeline.
They highlighted the importance of upcoming clinical trial results.
Bristol Myers Squibb's earnings report showed a slight miss on EPS, which contributed to a small decline in the stock price. Investors may be cautious due to the lack of revenue data and forward guidance. The management's focus on the product pipeline suggests they are looking to future growth despite current challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CANADIAN NATL RY CO
Oct 22, 2012